{"id":1547018,"date":"2026-05-20T13:36:58","date_gmt":"2026-05-20T11:36:58","guid":{"rendered":"https:\/\/laboklin.com\/autovaccines-as-a-treatment-option\/"},"modified":"2026-05-20T13:36:58","modified_gmt":"2026-05-20T11:36:58","slug":"autovaccines-as-a-treatment-option","status":"publish","type":"post","link":"https:\/\/laboklin.com\/no\/autovaccines-as-a-treatment-option\/","title":{"rendered":"Autovaccines as a Treatment Option"},"content":{"rendered":"

[vc_row][vc_column width=»2\/3″][vc_column_text]<\/p>\n

The problem of antibiotic resistance<\/h2>\n

Antimicrobial resistance (AMR) represents a serious threat to both animal and public health.
\nThe discovery of new antibiotic classes has been rare over recent decades (1). It has even been estimated that, without countermeasures, up to 10 million people per year could die from drug-resistant infections by 2050, exceeding the number of deaths caused by cancer (2).
\nAgainst this background, alternative treatment strategies such as individually produced, herd-specific vaccines (autovaccines) are becoming increasingly important. At European level, the promotion of alternatives to antimicrobial veterinary medicinal products has long been discussed as a key approach to reducing antibiotic use (3).<\/p>\n

Historically, autovaccines already experienced an initial peak in use at the beginning of the 20th century and, even before the discovery of the first antibiotic, penicillin by Alexander Fleming, were introduced by Sir Almroth Edward Wright (4\u20136).<\/p>\n

Wright developed individually prepared, heat-inactivated vaccines for the treatment of chronic staphylococcal infections, which were initially controversial (6).<\/p>\n

 <\/p>\n

Indications and efficacy of autovaccines<\/h2>\n

Autovaccines are used for the treatment of chronic and recurrent infections in which conventional therapeutic approaches have failed, or antibiotic treatment is not possible due to resistant pathogens.<\/p>\n

As an individual therapy, autovaccines aim to specifically stimulate the immune system of a single animal against the specific pathogen isolated from the site of infection. Autovaccines are therefore both pathogen- and patient-specific. They are not suitable for the treatment of acute diseases (6).<\/p>\n

The literature also describes further indications for autovaccines, such as use in cases of insufficient innate immune response or when suitable commercial vaccines are not available (6).<\/p>\n

Specific examples include the treatment of otitis externa, dermatitis, sinusitis, pharyngitis, and mastitis, involving both Gram-positive and Gram-negative pathogens (6).<\/p>\n

In dogs, autovaccines are particularly described for pyoderma and otitis externa and media (6). Mayr et al. report complete healing in 43.7% of dogs with pyoderma (7). Klein et al. observed a cure rate of 49% and slight improvement in 18% for the same indication following autovaccine treatment (8)[\/vc_column_text][\/vc_column][vc_column width=»1\/3″][vc_column_text]<\/p>\n\n\t\t\t